In the first three quarters, the net profit of the five pharmaceutical companies exceeded 3 billion yuan

[industry trends of pharmaceutical network] after the pharmaceutical companies finished half a year's report, the third quarter report also followed As of October 31, 276 pharmaceutical companies have published the third quarter results Through the third quarter report, we can find that the growth rate of the enterprise's income is on the whole expanding trend, the growth rate of the industry's overall income is slightly slower than that of the same period in the first half of the year, but the growth rate of the overall profit is on the rise As the net profit is an important indicator to reflect the sustainable operation ability of enterprises, the author focuses on the net profit of 276 pharmaceutical enterprises It is found that the net profit of 7 enterprises in January September exceeded 2 billion yuan, and 5 enterprises even exceeded 3 billion yuan Hengrui pharmaceutical: the net profit is 3.735 billion yuan According to the third quarter report issued by Hengrui pharmaceutical on October 24, the company's operating revenue in the first three quarters of 2019 was 16.945 billion yuan, a year-on-year increase of 36.01%; the net profit attributable to shareholders of listed companies was 3.735 billion yuan, a year-on-year increase of 28.26% In the third quarter, R & D cost reached 1.415 billion yuan, an increase of 90.96% compared with 741 million yuan in the same period of last year, and R & D investment reached a new high Hengrui's shares rose 5.8% and 4% respectively in the two trading days after the financial report was released due to the outstanding performance in the third quarter As of October 28, the stock price of Hengrui Pharmaceutical Co., Ltd was 91.08 yuan / share, up more than 70% in the year Mindray medical: the net profit is 3.671 billion yuan According to the public information, the operating revenue of Mindray medical in the first three quarters was 12379459320.00 yuan, an increase of 20.42% year-on-year The net profit attributable to the shareholders of the listed company was about 3.671 billion yuan, an increase of 26.74% year-on-year, and the performance was slightly higher than expected According to the announcement, the three major businesses of Mindray medical continued to maintain steady growth, and the growth rate of in vitro diagnosis increased The operating efficiency has been improved steadily, and the main cost indicators have shown a healthy performance As the leader of domestic medical devices, Mindray medical has established outstanding core competitive advantages in innovation research and development, channel sales, professional management, etc At present, the three businesses are still innovating, actively cultivating the field of minimally invasive surgery, and constantly enriching the product line In the future, it is expected to continue to enjoy graded diagnosis and treatment, encourage domestic policy dividends, and maintain steady growth in the long term Yunnan Baiyao: the net profit is 3542 million yuan On October 29, 2019, Yunnan Baiyao issued the third quarter financial report The report shows that Q3's revenue and net profit show a significant turning point The recovery and growth of drugs were significant, and the health products were also significantly improved The management cost decreased significantly, which increased the sales and R & D investment It is predicted that EPS will reach 3.11/3.57/4.09 yuan in 19-21 years, corresponding to 26 / 23 / 20 times of PE in 19-21 years With the continuous improvement of the pharmaceutical industry service system and the continuous upgrading of product and industrial quality, Yunnan Baiyao also complies with the trend According to the announcement, Yunnan Baiyao plans to use its own funds of 50 million US dollars (about 350 million yuan) to lay out biological drugs In addition, Yunnan Baiyao is also increasing its R & D efforts According to the financial report, the R & D investment of Yunnan Baiyao in the third quarter was 42.1196 million yuan, up 68.13% year on year Yunnan Baiyao shares rose 3.04% to close at 86.55 yuan per share as of October 31 Baiyunshan: the net profit was 3.160 billion yuan On October 28, Baiyunshan released the third quarter report According to the announcement, the company's operating revenue in the first three quarters was 5 billion yuan, up 67.57% year on year, up 67.57% year on year, and the net profit attributable to shareholders of listed companies was 3.16 billion yuan, down 8.13% year on year It is reported that the decline of net profit in the first three quarters of Baiyunshan is mainly due to the large base of recurring profit and loss in the first three quarters of 2018, and the sharp decrease of this profit in the first three quarters of 2019 The decline of gross profit rate and net profit rate is mainly related to the low gross profit rate of the consolidated financial statements of Wang Laoji and the pharmaceutical company SHP: net profit of RMB 3.07 billion On October 30, SHP also released the third quarter report of 2019 According to the report, the main business of SHP continued to grow rapidly from January to September, with an operating revenue of 140.617 billion yuan, a year-on-year increase of 19.57%, and a net profit attributable to shareholders of listed companies excluding non recurring profit and loss of 3.070 billion yuan, a year-on-year increase of 19.62% The net inflow of operating cash flow was 2.932 billion yuan, up 69.19% year on year In recent years, Shanghai Pharmaceutical has made great efforts to create a large variety, and promoted the overall rapid growth of the industrial sector through differentiated positioning and targeted marketing strategies During the reporting period, the sales revenue of 60 key varieties reached 10.154 billion yuan, a year-on-year increase of 31.19% From January to September, R & D expenses reached 860 million yuan, up 13.74% year on year 73 invention applications, 24 invention authorizations and 20 utility model authorizations were completed, totaling 117 In the future, SHP will continue to accelerate innovation and transformation, and invest more in innovative drugs and characteristic generic drugs.